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We thank Stadterman et al for their interest in our paper, and we would like to provide a few 
points of clarification. Although there is inconclusive evidence of harm regarding the sole 
use of marijuana during pregnancy and adverse birth and neonatal outcomes, in utero 
exposure to marijuana may lead to later learning and developmental impairments. Existing 
research, including our findings, suggests that concurrent use of other substances known to 
be teratogenic (ie, alcohol, tobacco) is common among marijuana users.
Guidelines from the American College of Obstetricians and Gynecologists recommend 
universal screening for all maternal substance use, irrespective of whether a substance is 
legal. Universal screening could be performed by maternal self-report during clinical 
encounters using validated screening tools as part of a woman's general health history.
The American College of Obstetricians and Gynecologists guidelines acknowledge the 
complex legal issues regarding universal screening and that punitive measures resulting from 
substance use screening are not “applied evenly across sex, race, and socioeconomic status.” 
However, the guidelines state that “in fulfillment of the therapeutic obligation, physicians 
must make a substantial effort” to “... practice universal screening questions, brief 
intervention, and referral to treatment in order to provide benefit and do no harm ...” and 
“protect confidentiality and the integrity of the physician-patient relationship wherever 
possible within the requirements of legal obligations, and communicate honestly and directly 
with patients about what information can and cannot be protected.” Thus, effective 
screening, as well as appropriate provider training and resources for patient education and 
care, is needed to support pregnant women who may want assistance with cessation.
Finally, we would like to clarify that women were asked in the National Surveys on Drug 
Use and Health whether they used marijuana in the past month and in the past year. They 
were then analytically coded as past month users and past 2–12 month users. We described 
the timing of pregnancy and past 2–12 month use as a limitation of this data source. 
However, because pregnant women were on average in their second trimester, past-month 
use is likely reflective of use during pregnancy. Our point estimate of 3.9% is within the 
range of use during pregnancy reported by individual states (2.6% Hawaii and 7.1% in 
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Alaska)., In the context of legalization, monitoring use of marijuana in pregnancy, as well as 
unintended consequences, is needed.
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